ATTBF - Abattis Bioceuticals Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue9/30/20179/30/20169/30/20159/30/2014
Total Revenue--91.947.72
Cost of Revenue--29.319-
Gross Profit--62.6217.72
Operating Expenses
Research Development24.69740.01682.791129.057
Selling General and Administrative5,436.7322,023.6782,554.9572,351.465
Non Recurring----
Others----
Total Operating Expenses6,300.9722,261.6493,091.3947,286.773
Operating Income or Loss-6,300.972-2,261.649-2,999.454-7,279.053
Income from Continuing Operations
Total Other Income/Expenses Net-1,625.144-150.534-2,993.494-372.348
Earnings Before Interest and Taxes-6,300.972-2,261.649-2,999.454-7,279.053
Interest Expense-3.041-6.323-18.69-9.046
Income Before Tax-7,926.116-2,412.183-5,992.948-7,651.401
Income Tax Expense---419.294-39.861
Minority Interest-753.23-461.176-383.906599.811
Net Income From Continuing Ops-7,926.116-2,412.183-5,573.654-7,611.54
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-7,634.062-2,339.416-4,472.547-7,569.411
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-7,634.062-2,339.416-4,472.547-7,569.411